Posted by AGORACOM-JC
at 7:51 AM on Tuesday, December 15th, 2020
Announced that it has been awarded two AI related contracts totalling $150,000 on the initial pilot contracts.
The first contract is for tech support for Incheon International Airport Corporation, a major airport in the Republic of Korea.
Company was also awarded a contract with ABL Life Insurance Co., Ltd. for job automation scheduling.
The Company commenced the work, and is already in negotiation to expand the scope of work and contract.
Toronto, Ontario–(December 15, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that it has been awarded two AI related contracts totalling $150,000 on the initial pilot contracts.
The first contract is for tech support for Incheon International Airport Corporation (“IIAC”), a major airport in the Republic of Korea.
Under the terms of the contract, Datametrex will provide AI for job automation scheduling using AI technologies in partnership with third party software from Sees solutions for Workload Automation-As-A-Service (“WAAAS”). The batch job scheduler will help automate the workflow with all batch jobs that are software managed and approve the results of the execution by WAAAS. Integrated batch job scheduler systems are linked to the existing legacy system and each target system is configured to execute batch jobs. Once operational, the system will feature integrated batch job management, flexible approval system, efficient calendar management, secure security, optimal performance, and agent add-in are features that manage file transfer functions.
The Company was also awarded a contract with ABL Life Insurance Co., Ltd. (“ABL”) for job automation scheduling. The Company commenced the work, and is already in negotiation to expand the scope of work and contract.
About Incheon International Airport Corporation
Seoul Airport, known officially as Incheon International Airport (IATA: ICN, ICAO: RKSI), and is the largest and the primary airport serving Seoul, the capital of South Korea. The airport employs over 40,000 people and include airport management staff, security personnel and system managers.
It is located west of Incheon city and 30 miles (48 km) west of Seoul. Incheon Airport consists of two passenger terminals, and has 111 boarding gates altogether, with 44 in Terminal 1, 30 in Concourse A (connected to Terminal 1), and 37 in Terminal 2. It has been rated as the one of the world’s cleanest airports and highly rated international transit airports by Skytrax. In 2019, the airport served a total of 70,857,908 passengers and ranked 8th in international passengers and 3rd in international cargo. Additional information on Incheon is available at www.airport.kr/
About ABL Life Insurance Co., Ltd
Founded in 1954, ABL Life provides insurance products and financial services to 1.13 million customers based on a nationwide sales network. ABL Life Insurance is striving to become “a reliable global life insurance company that provides ‘better life’ through advanced products and smart services.” Additional information on ABL is available at www.abllife.co.kr/
About Datametrex
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.
For further information, please contact: Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.
Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.
Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 7:47 AM on Friday, December 11th, 2020
Though the Company has not commented on the tweet publicly, several inquires on the tweet have been put to management.
What the Company can confirm is that Datametrex is completing an agreement to support Canadian communities and provide pre-departure coronavirus (COVID-19) PCR-based testing for travellers in several large metropolitan centers within Canada.
These tests will be available for travellers flying to any destination requiring a negative COVID-19 test.
Toronto, Ontario–(December 11, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) wishes to provide clarity on a statement that was published on Twitter by Air Canada regarding COVID-19 testing and Datametrex on November 22, 2020.
The official Air Canada Twitter channel @AirCanada replied to a tweet on a question posted regarding COVID-19 trusted testing partners for travel to the state of Hawaii. Air Canada provided the following reply, “The state of Hawaii will only accept COVID-19 PCR – Nucleic Acid Amplification Test (NAAT) from a certified Clinical Laboratory from trusted testing and travel partners. In Canada those are: LIFE LABS, DYNACARE, Datametrex Al limited, Biron, and DynaLIFE MEDICAL LABS. /Ariana.”
Though the Company has not commented on the tweet publicly, several inquires on the tweet have been put to management. What the Company can confirm is that Datametrex is completing an agreement to support Canadian communities and provide pre-departure coronavirus (COVID-19) PCR-based testing for travellers in several large metropolitan centers within Canada. These tests will be available for travellers flying to any destination requiring a negative COVID-19 test.
As a trusted testing and travel partner, Datametrex will provide further commentary in a news release on locations and specifics to the COVID-19 testing for travellers. Datametrex believes that testing and peace of mind are important to your health and wellness.
Important COVID-19 Considerations
Note: Health Canada does not advise you to get a COVID-19 test if you do not have symptoms of the virus. Since a negative result is required for the Hawaiian pre-testing program, this would go against public health advice.
The Government of Canada also warns against travel outside of the country. Due to the COVID-19 pandemic, governments that have opened their borders to tourists could impose strict travel restrictions suddenly, which could make it difficult for you to return home.
Under measures from provincial Governments in Canada, all arriving passengers from outside of Canada, regardless of their final destination, are required to submit a self-isolation plan. It must show that returning passengers have supports in place to safely self-isolate for 14 days.
About Air Canada
Air Canada is Canada’s largest domestic and international airline. Canada’s flag carrier is among the 20 largest airlines in the world and in 2019 served over 51 million customers. Air Canada is a founding member of Star Alliance, the world’s most comprehensive air transportation network. Air Canada is the only international network carrier in North America to receive a Four-Star ranking according to independent U.K. research firm Skytrax, which also named Air Canada the 2019 Best Airline in North America. For more information, please visit: aircanada.com/media.
About Datametrex
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.
For further information, please contact: Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.
Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.
Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the time such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 11:53 AM on Thursday, December 10th, 2020
Datametrex AI Limited (DM:TSXV) (D4G:FSE) (DTMXF: OTC) an AI and Machine learning company was well positioned with deep roots in South Korea to make the ultimate pivot to Covid-19 test kit distribution. When the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.
Since then, the company has signed multiple multi-million dollar Covid-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions. This is in addition to lucrative AI contracts with various levels of government and enterprise level customers such as LOTTE Group, the fifth-largest conglomerate in Korea with annual revenues of approximately $60B USD.
REVENUE $CAD
Q1 + 62% To $809,000
Q2 + 419% To $1,954,000
Q3 + 188% To $4,862,325
TOTAL Q1/Q2/Q3
REVENUE $7.6M vs $2.6M = +192%
GROSS PROFIT $2.3M vs $961K = +139%
Here’s the recent headlines:
Completion of the IDEaS program Component 1b Milestone 4 (December 9, 2020)
Recognized revenue of $7.6 million for first 9 months of 2020 (November 25, 2020)
Datametrex Expands Distribution of Film and Television Coronavirus Testing Across Canada (October 27, 2020)
Expands to Toronto Film Production Company for COVID-19 Testing Solutions (September 30, 2020)
$20M Supply Agreement With Major Worldwide Media & Entertainment Company for COVID-19 (September 24, 2020).
Received Third COVID-19 Order from TV Production Company (September 21, 2020)
Received COVID-19 Test Kits Order for $1.6M From a Canadian Mining Company (September 3, 2020)
The demand for Covid testing is robust and well documented by the following:
U.S. television productions stalled in Vancouver by bottleneck in COVID-19 testing Read More
As tweeted by Air Canada on November 22, 2020:
Prior to the global pandemic, leaders embraced advanced analytics and AI, for good reason. According to a 2018 study by the McKinsey Global Institute, entitled: Notes from the AI frontier: Applications and value of deep learning, these capabilities are estimated to have the potential to create between approximately $9.5 trillion and $15.4 trillion in annual global economic value.
The company’s wholly owned subsidiary Nexalogy also played a key technology support role in the #SeeSay2020 campaign to fight voter intimidation in this past USA election. The company’s AI technology allowed for cyber filtration to identify voter intimidation for elections related research.
The company has also experienced robust demand for related services. Datametrex entered into a sales agreement with 7-Eleven Korea for Robotic Process Automation infrastructure (RPA) in order to automate certain business processes.
The global RPA market size is expected to reach $7.2 billion by 2025, rising at a market growth of 32.6% CAGR during the forecast period. RPA is the technology that enables anyone to configure computer software today, or a “robot” to replicate and incorporate the actions of a person working within digital systems to conduct a business process.
Posted by AGORACOM-JC
at 9:43 AM on Wednesday, December 9th, 2020
Announced the completion of the IDEaS program Component 1b Milestone 4, as well as the launch of Nexalogy’s Social Media Automated Reporting Technologies (“SMART”)
The Company will receive approximately $218,000.00 CAD for the Component 1b Milestone 4. Combined, the total for all Milestones in Component 1b is approximately $945,000.00 CAD
Toronto, Ontario–(December 9, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC: DTMXF) (the “Company” or “Datametrex”) is pleased to announce the completion of the IDEaS program Component 1b Milestone 4, as well as the launch of Nexalogy’s Social Media Automated Reporting Technologies (“SMART”). The Company will receive approximately $218,000.00 CAD for the Component 1b Milestone 4. Combined, the total for all Milestones in Component 1b is approximately $945,000.00 CAD.
As previously announced, Nexalogy’s SMART is an advanced proprietary AI technology. SMART minimizes human involvement in data analysis and reporting. It significantly decreases the time required for integration and interpretation of large data sets and report production. Nexalogy has completed the IDEaS Component 1b Milestone 4, and as a result, SMART has been tested internally with several existing clients. It is expected to be fully available in Q4 of 2020.
AI reporting on social media and other forms of unstructured text is increasingly important. Global developments in the information landscape, as well as the increased importance of telework with the COVID-19 pandemic, have both contributed to the need for strategic reporting of data from these platforms. In terms of automation, SMART helps to reduce the time involved in the analysis and management of the data deluge. In terms of objectivity, SMART helps to reduce human bias and error when dealing with big data. SMART increases efficiency for an extra layer of defence against terrorism, pandemics, and overall crises, as well as providing clients with an edge to be ahead of social trends, competitors, and new audiences.
“We are very happy to have successfully completed the IDEaS Component 1B Milestone 4 and the launch of SMART,” said Marshall Gunter, President and CEO of the Datametrex AI Limited. “Datametrex has put significant effort into the R&D behind SMART, which is a major goal of the IDEaS program. We are confident that our cutting edge technology will significantly benefit our clients. We look forward to deploying this technology in new verticals.”
About SMART (Social Media Auto-Reporting Technologies)
SMART reduces the time needed to interpret and integrate large sets of data by offering powerful automated analyses. Rather than replacing the human analyst, he/she sets the parameters of the data collection via keywords and other social media information (e.g., usernames and links). This allows for the identification of data needing extraction and analysis. SMART extracts the relevant data and produces automated reports, thus allowing clients to work with a more manageable information set. SMART allows an analyst to deal with hundreds of thousands of social media documents in minutes rather than hours or days.
Analysts can specify filters on the data to get automatic reports on subsets of the data focusing on specific times, entities, social media users, or topics. The resulting reports are delivered either as PDFs, DOCs, or via API for further processing. The report generation can be scheduled to occur either at regular intervals or to be triggered by specific changes in the conversation (e.g., a sudden increase in volume or an increase in mentions of a particular named entity).
Lastly, SMART analysis helps the user to easily access the required information and helps to detect patterns that currently go unrecognized. This is needed in both the context of the ‘short game’ of crisis reporting and the ‘long game’ of identifying narratives, as discussed within the BEND (Build Engage Neutralize Distract) framework.
For more information about the technology, please reach out to us.
About IDEaS
IDEaS, an initiative by the Canadian Government, supports the development of solutions from their conceptual stage, through prototype testing and capability development. The program includes several elements that promote collaboration between innovators, provide developmental resources and provide opportunities to interact with DND’s science and military members. In this way all innovators are on an even playing field to solve specific defence and security challenges. For more info about the program, see here: https://www.canada.ca/en/department-national-defence/programs/defence-ideas.html
About Datametrex
Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.
For further information, please contact: Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Neither the TSX Venture Exchange nor it Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 8:12 AM on Wednesday, December 2nd, 2020
Announced that the manufacturer of 1copy™ COVID-19 qPCR Multi Kit (“qPCR kit”) has made available the new testing method and technology with improvements related to testing time.
The qPCR kit has reduced the processing time with a polymerase chain reaction (“PCR”) machine to 45-50 minutes.
This is significant compared to other test kits available in the market for the same category of tests that can take up to 2 hours for similar test results.
As a result, management of the Company anticipates that this will help in the service of the Company’s current projects especially when processing large film crews which will enhance the turnaround times for test results on these multi-million dollar productions.
Toronto, Ontario–(December 2, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that the manufacturer of 1copy™ COVID-19 qPCR Multi Kit (“qPCR kit”) has made available the new testing method and technology with improvements related to testing time.
The qPCR kit has reduced the processing time with a polymerase chain reaction (“PCR”) machine to 45-50 minutes. This is significant compared to other test kits available in the market for the same category of tests that can take up to 2 hours for similar test results. As a result, management of the Company anticipates that this will help in the service of the Company’s current projects especially when processing large film crews which will enhance the turnaround times for test results on these multi-million dollar productions.
The Company also sees a benefit of rapid results as it navigates into the travel industry as it looks at processing passengers at cruise ship terminals, and with airport authorities, to reduce the risk of transmission of the virus. These potential testing projects represent an important shift towards getting the travel industry back on its feet over the next year and supporting business travellers and vacationers looking to safely take a trip abroad.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
Investor Webinar
Datametrex also announces that its senior management will be hosting an investor update webinar on Thursday, December 3, 2020, at 1:30 p.m. EST to discuss the Company’s Third Quarter 2020 results, developments, and contracts on the Artificial Intelligence technologies and COVID-19 test kits.
Datametrex plans to answer questions previously sent to [email protected] and during the webinar, at management’s discretion and subject to time constraints.
The Company’s Financial Statements (“FS”)and Management Discussion & Analysis (“MD&A”) are available at the nine months ended September 30, 2020 are available on the Company’s profile at SEDAR at www.sedar.com.
About 1drop Inc.
1copy™ COVID-19 qPCR Kit is approved by Health Canada (“HC”), Kingdom of Saudi Arabia-Saudi Food & Drug Authority (“SFDA”) approval, and CE marking certification (“CE”) for European Economic Area (“EEA”) countries, which covers the 27 member states of the EU, the 4 members of the European Free Tarde Association (the “EFTA”), plus Turkey and the United Kingdom under Brexit. It is a nucleic test kit that verifies RdRp gene for SARS-CoV-2 with the qPCR kit via nasopharyngeal swab and oropharyngeal swab and specifically targeting the E gene sequences of COVID-19. The kits are made by 1drop Inc. located in Jungwon-gu, South Korea, and was incorporated in 2017 following a technology spin-off from Samsung electronica’s C-Lab program. Samsung Electronica’s C-Lab located in South Korea is an internal incubation program that first started in 2012 to help inspire a more creative company culture.
For more information please consult the website at: 1drop
About Datametrex
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.
For further information, please contact: Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.
Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.
Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 11:41 AM on Wednesday, November 25th, 2020
Recognized revenue of $7.6 million
Earned $362K excluding non cash expenses
Very strong balance sheet with $1.4M cash and $2M receivables
Introduced Naxalogy’s Social Media Automated Reporting Technologies.
Completed the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security IDEaS program.
Toronto, Ontario–(November 25, 2020) – Datametrex AI Limited(TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex“) is pleased to announce record third quarter 2020 (“Q3”) financial and operating results. All currency is in Canadian dollars, unless otherwise stated. All results are reported on a 100% basis.
The Company’s revenue increased by 189% in Q3 compared to the same period of last year. The Company’s cash position improved significantly to $1,413,374 compared to $119,675 at the end of 2019. The net loss improved with a decrease of 35% to ($451,353) compared to ($695,803) in the same period of last year. There was a $607,997 of option issuance expense and $194,517 of Depreciation and Amortization expense, which are non-cash based expenses.
Excluding these expenses, the Company generated a net profit. This is reflected in Adjusted EBITDA. The Adjusted EBITDA showed a significant improvement achieving a positive Adjusted EBITDA of $362,059, compared to ($539,116) in the same period of last year.
“In Q3 2020, the Company achieved multiple key milestones, a significant increase in gross revenue and improvement in its cash position. This positive outcome was a direct result of our quick response in implementing a plan to begin selling test kits as result of the global impact of the COVID-19 virus. This resulted in a substantial improvement to the bottom line,” said Marshall Gunter, CEO of the Company.
Business Outlook
AI and Technology
The Company is now targeting larger bids with the Canada’s Industrial and Technological Benefits (“ITB”) program that are in the range of tens of millions of dollar. At the same time, we are continuing to work with the United States Air Force (“USAF”), Office of Naval Reesarch (“ONR”) and the Defence Research and Development Canada (“DRDC”).
The Company is also continuing to expand its product and, as such, Nexalogy SMART technology will be available imminently on the market.
Our footprint in Korea continues to expand as demonstrated by the recent growth in our revenue. We are looking to bring the formula used in Korean sales to Canada and the United State for the private sector.
COVID-19 Test Kits
The Company continues to expand our footprint with film production companies and mining companies, performing approximately 5,000 tests a week. We expect the number of tests per week to grow continuously as the Company is now running tests in Vancouver, Toronto and Montreal.
Highlights for Q3 2020
Recognized revenue of $7.6 million for the nine-month 2020 period compared to $2.6 million in same period 2019, of which $4.9 million was earned in the third quarter.
The Company started securing and delivering purchase orders of COVID-19 test kits and generated $2.3 million COVID-19 related revenue in Q3 2020.
The Company has received $1.8 million from the exercise of share purchase warrants and options.
The Company introduced Naxalogy’s Social Media Automated Reporting Technologies.
The Company completed the second phase of a multi-phase R&D program through the Department of National Defence’s Innovation for Defence Excellence and Security IDEaS program.
Financial Highlights
The following table summarizes revenue, net loss and EBITDA* and Adjusted EBITDA* for the three and nine months ended September 30, 2020 and 2019.
* Note: EBITDA (non- IFRS measures) is calculated as Net Loss adjusted for 1. Income taxes, 2. Depreciation and amortization, and 3. Interest and accretion. Adjusted EBITDA (non-IFRS measures) is calculated as EBITFA adjusted for share based compensation.
Non-IFRS financial measures do not have standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Specific items may only be relevant in certain periods. For reconciliation of non-IFRS financial measures please refer to the Company’s Management Discussion and Analysis for the nine months ended September 30, 2020.
The Company’s Financial Statements and Management Discussion & Analysis (“MD&A”) are at SEDAR at www.sedar.com.
About Datametrex
Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational Health and Safety goals with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain.
Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 12:18 PM on Thursday, November 12th, 2020
The devastation and destruction of Coronavirus COVID-19 is well documented and doesn’t need much repeating here.
What we do know is that COVID-19 has created global demand for highly specialty products required to protect, test, detect and defend as many people as possible.
Moreover, given its persistence and the potential for a 2nd wave around the world, governments and businesses both big and small are now in need of solutions that go beyond locking down economies by helping them stay open, generate revenue, keep people employed … all while keeping them safe.
There are no magic bullets. COVD-19 didn’t exist 12 months ago, so there are no established or incumbent leaders. This has created an opportunity for small but nimble companies with high-tech expertise to adapt their products as solutions in one of the many verticals that require help fighting COVID-19.
Here are 6 small-cap companies (in alphabetical order) that have provided real solutions to helping the fight against COVID-19.
Datametrex AI Limited (DM:TSXV) (D4G:FSE) (DTMXF: OTC )an AI and Machine learning company was well positioned with deep roots in South Korea to make the ultimate pivot to Covid-19 test kit distribution. When the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.
Since then, the company has signed multiple multi-million dollar Covid-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions. This is in addition to lucrative AI contracts with various levels of government and enterprise level customers such as LOTTE Group, the fifth-largest conglomerate in Korea with annual revenues of approximately $60B USD.
REVENUE $CAD
Q1 + 62% To $809,000
Q2 + 419% To $1,954,000
TOTAL Q1 AND Q2
REVENUE $2.8M vs $875K = +220%
GROSS PROFIT $1.2 vs $739K = +62%
Given the speed of incoming contracts, the quarterly financials don’t reflect deals done during the third quarter. Here’s just a few;
Datametrex Expands Distribution of Film and Television Coronavirus Testing Across Canada (October 27, 2020)
Expands to Toronto Film Production Company for COVID-19 Testing Solutions (September 30, 2020)
$20M Supply Agreement With Major Worldwide Media & Entertainment Company for COVID-19 (September 24, 2020)
Received Third COVID-19 Order from TV Production Company (September 21, 2020)
Received COVID-19 Test Kits Order for $1.6M From a Canadian Mining Company (September 3, 2020)
·· The company has also experienced robust demand for related services. Datametrex entered into a sales agreement with 7-Eleven Korea for Robotic Process Automation infrastructure (RPA) in order to automate certain business processes.
The global RPA market size is expected to reach $7.2 billion by 2025, rising at a market growth of 32.6% CAGR during the forecast period. RPA is the technology that enables anyone to configure computer software today, or a “robot” to replicate and incorporate the actions of a person working within digital systems to conduct a business process.
For more information, please visit the Datametrex AI hub on AGORACOM.
Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for …. but that’s not all. In an effort to combat COVID-19 the company’s physician staffed clinics have are also generating significant revenue and growth as follows:
Increased CBD treatments from patients suffering increased anxiety;
Covid-19 Testing for individuals and families
Covid-19 Testing for local businesses and employees
Covid-19 Testing for enterprise level organizations across the country
Empower Clinics and Loop Insights Combine COVID-19 Testing Expertise With Venue Tracing To Create First Ever “Travel Bubble” Solution For Global Travel Industry Set To Lose $3.3 Trillion
How significant is this acquisition that only closed a couple of weeks ago? At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY.
Patient Visits
Q1 + 377% To 5,717
Q2 + 56% To 6,696
Revenues $USD
Q1 + 416% To $790,000 (NO COVID)
Q2 + 56% To $923.000
TOTAL Q1 AND Q2
REVENUE $1.7M vs $745K = + 130%
PATIENTS 12,400 vs 5,500 = + 125%
NET LOSS $920K vs 1.85M = – 50%
Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.
Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never. Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.
For more information about the company, please check out the Empower HUB on AGORACOM.
Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is an Israeli based company developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.
Innocan, together with Tel Aviv University are developing new, revolutionary exosome based technology (CLX), loaded with cannabidiol (CBD) targeting the coronavirus infected lung cells.
Why is this significant?
CLX may hold the potential to provide anti-inflammatory properties and assist in the recovery of infected lung cells. It is expected to be administrated by inhalation, CLX will be tested on a variety of lung infections focusing on patients infected by the coronavirus disease.
Superior Management Team
More than just lip service, Innocan has a world class management team to make this happen.
In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself. The Innocan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:
Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
While the Company develops their pharmaceutical solution, Innocan has a portfolio of patent-pending and launch ready consumer health products that are already commercializing around the world as follows:
CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.
Global Manufacturing / Distribution Agreements
To support this global growth, Innocan already has the following relationships in place:
Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.
Kontrol Energy is the Google NEST of smart building technology, with a Blue Chip client base to prove it with the likes of Beyond Meat, Toyota, Oxford, Telus and Brookfield to name a few.
As a result, Kontrol is already achieving commercial success as follows:
· Q1 $2.3M
· Q2 $2.7M
TOTAL Q1 AND Q2
REVENUE $5M
GROSS PROFIT $2.7M
ADAPTING CORE TECH TO PROVIDE BLUE CHIP CUSTOMERS WITH REAL-TIME AIR DETECTION OF COVID-19 IN COMMERCIAL BUILDINGS
As a result of the COVID-19 pandemic and the needs of its blue chip customer base, Kontrol is adapting its core technologies team to development and commercialize its Kontrol BioCloud® analyzer, a wall-mounted technology which detects the presence of COVID-19 in the air of commercial buildings and triggers an alert system to provide real time notifications.
GEARING UP PRODUCTION FOR UP TO 20,000 UNITS PER MONTH
Initial expectations, based on lab testing completed to date, is that BioCloud will be effective in small to medium space settings with 3 or more people, and therefore would be suitable for areas such as classrooms, offices, airplanes, trains, buses, long-term care facilities and hospitals. The company is currently building a global supply chain with the goal of being able to supply 20,000 units per month.
The implications of the Kontrol BioCloud® analyzer could be enormous and could have a major impact on the global economy. Paul Ghezzi, CEO of Kontrol Energy has received calls from interested parties spanning the entire globe. In addition, mainstream media has taken notice:
Early tests suggest new Canadian technology could detect the coronavirus in the air Read More
Canadian firm develops tech to ‘detect COVID-19 in the air’; stock doubles Read More.
Kontrol Energy’s BioCloud Featured By Singapore’s IBI Times Read More
CSA APPROVAL RECEIVED ON NOVEMBER 5TH
On Novebmer 5th, KNR announced receipt of CSA standards approval for its BioCloud® technology.
“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol. “CSA is a Canadian standard for safety and is also accepted in jurisdictions outside Canada. In addition to CSA we continue to work on other important regional certifications including UL and CE for the United States and European markets respectively.”
UL STANDARDS APPROVAL RECEIVED NOVEMBER 12TH
“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”
DISCLAIMER: The Company has not made any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
For more information about the company, please check out the Kontrol Energy hub on AGORACOM.
Loop Insights (MTRX:TSXV)(RACMF:OTCQB) was already a leading provider of contactless solutions and artificial intelligence (“AI”) to the brick and mortar space prior to the arrival of COVID-19.
Over the last few months Loop has adapted its contactless platform to also provide contact tracing and real-time testing to large venues and businesses. More than just lip service, Loop has already announced significant partnerships and news with the likes of:
“By partnering with innovative and leading IoT development companies, such as Loop, we’re ensuring that our customers have access to some of the most advanced IoT business solutions in the world.”
The presentation ended at approximately 1:15 PM EST, and by 8:00 PM EST Loop had received over 100 direct inquiries from enterprise-level attendees spanning many different industries and countries. Loop Insights anticipates many more direct inquiries to be received in the coming days.
Loop Insights CEO Rob Anson:
“We knew going into the webinar that interest in our Contactless Platform and Solutions was very high given the high-level nature of clients we had already announced leading up to it. These attendees, many of whom represent household name entities, were looking to us for solutions that can protect people, instill confidence in their customers and get their enterprises moving once again. Nonetheless, the response to the demonstration of our Contactless Venue Tracing Platform was simply incredible and even surpassed our expectations. We are optimistic that Loop Insights is establishing an identity as a global force in the contactless space and believe the responses will lead to significant business for Loop. We can’t thank Amazon Web Services enough for their continued support and partnership.”
In addition to these successes, Loop stated that its Venue Tracing platform is clearly gaining recognition and third-party validation, including implementations with:
Implemented Into the Las Vegas flagship properties of a Global Hospitality company (July 23, 2020)
Invited by NCAA DIV 1 BIG EAST CONFERENCE To Present Solution For 11 schools (August 17, 2020)
Partnership with BDG sports to deliver NBA, NHL, NCAA and PGA Sporting Events. (August 13, 2020)
Loop Insights Signs $1,930,000 USD License Deal with Austin, TX Based CasaPerks (September 28, 2020)
Selected as the Premier Venue Tracing and Fan Engagement Solution for NCAA College Basketball “Bubble” in Las Vegas (October 8, 2020)
For more information about the company, please check out the Loop Insights hub on AGORACOM.
Primo Nutraceuticals, a player in the hemp space pivoted early in the pandemic to sell their Primo Lemon Hand Sanitizer in Amazon’s Personal Safety & Household category. The company further solidified its move to PPE by entering into agreement with Duquette Consulting LLC, a company owned by Dan Duquette.
Dan Duquette is a twice named Major League Baseball (MLB) Executive of the Year and former Executive Vice-President of the Baltimore Orioles, General Manager of the Montreal Expos, Boston Red Sox, and Milwaukee Brewers (https://en.wikipedia.org/wiki/Dan_Duquette). Dan Duquette has joined forces with Primo Nutraceuticals to partner in the development, sourcing and the global supply of personal protective equipment products.
The company has been issued a Medical Device Establishment License from Health Canada.The MDEL is a license issued to companies for the activities of manufacturing, importing and distributing of all four classes of medical devices for human use in Canada. These classes include; nitrile gloves, N95 surgical masks & KN95 masks, surgical gowns, respirators and testing kits to name a few.
The PPE Distribution Market worth $28.9 Billion by 2025 in North America and E.U
The North America and Europe distribution market for PPE is expected to reach US$28.95 M by 2025.
The safety-supplies sector in North America is anticipated to witness significant growth of over 7% from 2017 to 2025.
Head, eye and face protection are anticipated to grow at a compound annual growth rate of over 6% from 2017 to 2025.
For more information about the company, please check out the Primo Nutraceuticals hub on AGORACOM.
Thanks for reading and discovering these great small cap companies. Please be sure to visit the AGORACOM Small Cap Coronavirus Covid-19 company gateway often to stay up to date with new companies at:
Posted by AGORACOM-JC
at 10:43 AM on Tuesday, October 27th, 2020
Currently, supplying COVID-19 Tests for thirteen film productions launched in Vancouver, with additions in Montreal, and Toronto.
Currently executing over 4000 tests per week.
Top-line revenue estimates from the current work is approx. $20 million.
Toronto, Ontario–(October 27, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF)(the “Company” or “Datametrex”) is pleased to update its shareholders on the growth of film and television production COVID TESTING. As Film and Television studios continue to expand productions throughout Canada, Datametrex is being requested by its current clients to take on more coronavirus testing for their portfolio of productions across the country.
The Company has also been approached by additional film and studio companies for Datametrex to assist with fulfilling the studio with their own testing needs. Based on these current contracts, and additional opportunities for testing services which the Company is pursuing and in discussions for, management believes that the Company is on track to achieve approximately 4,000 tests per week, based on current operations Datametrex, current cost and revenue model, would result in revenue of approximately $20 million over the next 28 weeks. There can be no assurance or guarantee that this revenue amount will result for the Company.
The global film and video market is expected to decline from $252.9 billion in 2019 to $244.4 billion in 2020 at a compound annual growth rate (CAGR) of -3.4%. The decline is mainly due to economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it. The market is then expected to recover and grow at a CAGR of 5% from 2021 and reach $284 billion in 2023.
Marshal Gunter, CEO, said, “I must first say thank you to the entire team at Datametrex along with the medical and lab professionals for their tireless work at the company. We are ramping up our business to meet increasing demand and our expectation based on what we are seeing in the market is to execute on approximately 10,000 tests per week on a progressive basis. We are witnessing a paradigm shift within the film industry. With the advent of movie theaters being closed in numerous regions around the globe due to government enforced shut downs by coronavirus, film and television companies rely more on at-home streaming services to maintain a robust revenue model. Content production is key to this and Canada is a major platform for content development. The demand remains high for qualified medical professionals from the private sector to be on site, and in the lab, ensuring complete and timely delivery of coronavirus tests supplied by Datametrex.” He continued, “with our growing revenue model, we remain committed to our shareholders and will announce further developments with additional conference calls and press releases in the coming weeks.”
About Datametrex
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.
For further information, please contact:
Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated as disclosed in this press release.
Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.
Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 7:26 AM on Friday, October 16th, 2020
Announced that its wholly owned subsidiary Nexalogy is playing a technology support role in the #SeeSay2020 campaign to fight voter intimidation in the upcoming USA election to be held on November 3rd, 2020.
“We are happy to be a supporting technology provider for Democracy Labs and SeeSay2020,” says Marshall Gunter, CEO of the Company. “The 2020 U.S. election is likely to cost nearly $11 billion, making it by far the most expensive election in U.S. history, according to projections by a leading campaign finance watchdog”
AI driven mapping technology allows for cyber filtration to identify voter intimidation for elections related research
Toronto, Ontario–( October 16, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC PINK: DTMXF) (the “Company” or “Datametrex“) is pleased to announce that its wholly owned subsidiary Nexalogy is playing a technology support role in the #SeeSay2020 campaign to fight voter intimidation in the upcoming USA election to be held on November 3rd, 2020.
“We are happy to be a supporting technology provider for Democracy Labs (“DemLabs”) and SeeSay2020,” says Marshall Gunter, CEO of the Company. “The 2020 U.S. election is likely to cost nearly $11 billion, making it by far the most expensive election in U.S. history, according to projections by a leading campaign finance watchdog. (source: https://www.voanews.com/2020-usa-votes/2020-us-election-cost-approaching-record-11-billion). Our AI driven mapping technology allows for cyber filtration to identify voter intimidation for elections related research.”
Incidents of voter suppression and intimidation have to be highlighted quickly. How can this be done with so much activity in such a short period of time with disinformation filling the airwaves? A citizen reporting system that can quickly distill information and share it with groups best equipped to deal with that incident is needed. For this purpose DemLabs has aligned several leading technology partners, including Nexalogy to support the SeeSay2020 platform.
DemLabs has selected Nexalogy to collect data of incidents reported of voter suppression through Twitter. Nexalogy throughts its technology platform monitors tweets for keywords that DemLabs chose including “VOTER”, “SUPPRESSION”, “INTIMIDATION” and “LONG LINES”. This allows the SeeSay2020 campaign to pay close attention (geofence) to tweets originating from certain counties and cities prone to voter suppression.
Working in conjunction with DemLabs and other technology partners See Something, Say Something was first deployed in the 2018 mid-terms along with Trust The Vote, NBC, Samantha Bee and Rock The Vote. It collected over 2,000 reports of voting issues which can still be seen on the SeeSay2020 dashboard. The data collected was shared with other groups for legal and analysis purposes.
Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational Health and Safety goals with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain.
Democracy Labs is a hub for ongoing technology and creative innovation that serves progressive campaigns and organizations at the national, state, and local levels. Our focus is on long term, sustainable and affordable solutions. An approach that is longer than an election cycle, and isn’t purely dependant on volunteers, can enable more qualified candidates to run for office and for more issue groups to bring about positive social change. Democracy Labs is a project of the Tides Advocacy Fund.
For further information, please contact: Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 9:52 AM on Thursday, October 15th, 2020
Company has started to deploy in the market MiCovid Cam Temperature Scanners with COVID-19 testing customers
Product is a new AI thermal detector with facial recognition and non-contact temperature assessment device to identify and triage people who may have elevated temperatures
Utilizing the latest AI chipset technology, MiCovid Cam offers immediate body temperature detection, a long sensor range, and a high level of accuracy
Toronto, Ontario–(October 15, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that the Company has started to deploy in the market MiCovid Cam Temperature Scanners with COVID-19 testing customers from October 9, 2020. This product is a new AI thermal detector with facial recognition and non-contact temperature assessment device to identify and triage people who may have elevated temperatures.
Utilizing the latest AI chipset technology, MiCovid Cam offers immediate body temperature detection, a long sensor range, and a high level of accuracy. MiCovid Cam is fully integrated into Web Services API suite allowing third party and independent software developers to adopt body temperature data into their current and future software solutions. It is fast, non-contact, non-invasive and accurate so as to not delay or hamper the customer experience.
“As we potentially enter into a second wave of the COVID-19 there is a need to support the reopening of economies, and having another tool to support this with MiCovid Cam, which is a solution capable of fast tracking the safe return of customers to office buildings, restaurants, retail outlets, coffee shops, government offices, and educational institutions.”, commented Marshall Gunter CEO of the Company.
The Company issued 2,500,000 stock options with an exercise price of $0.12 to a consultant pursuant to its stock option plan on October 7, 2020.The options will expire on October 1, 2023.
The Company also wishes to clarify certain statements included in its press release dated October 1, 2020 (the “CEO Update Release“). Certain statements included in the CEO Update Release constitute “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements contained in the CEO Update Release include statements with respect to the Company’s intention regarding possibility of consolidating its common shares and the Company’s anticipated profitability. The Company cautions readers that these forward-looking statements are not historical facts and may have involved estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. Specifically, forward-looking statements contained in the CEO Update Release were based on certain assumptions made by management of the Company, including with respect to the projected growth of the market for the Company’s products, the Company’s ability to meet customers’ product demand, the projected financial performance of the Company, the Company’s ability to obtain and maintain all necessary government approvals to operate its business and the absence of any unforeseen logistical delays in the Company’s growth including those related to COVID-19. No assurance can be given that these expectations will prove to be correct. Undue reliance should not be placed on the forward-looking statements included in the CEO Update Release. The forward-looking statements included in the CEO Update Release were made as of the date of the CEO Update Release. The Company has undertaken no obligation to update or revise any forward-looking statement included in the CEO Update Release to reflect events or circumstances after the date on which such statements were made or to reflect the occurrence of unanticipated events, except as required by applicable securities laws.
About Datametrex
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.
For further information, please contact: Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.
Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.
Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
